Nucleotide sequence divergence and functional constraint in VIP precursor mRNA evolution between human and rat

Mikio Nishizawa, Yumiko Hayakawa, Noboru Yanaihara[†] and Hiroshi Okamoto*

Department of Biochemistry, Toyama Medical and Pharmaceutical University School of Medicine, Toyama 930-01, [†]Laboratory of Bioorganic Chemistry, Shizuoka College of Pharmacy, Shizuoka 422, and *Department of Biochemistry, Tohoku University School of Medicine, Sendai 980, Miyagi, Japan

Received 25 January 1985

The nucleotide sequence analysis of cloned cDNA for VIP precursor from rat cerebral cortex reveals that the precursor contains both rat VIP and PHI-27. The deduced primary structure of rat VIP is identical with human VIP. The amino acid sequence of rat PHI-27 differs by 4 amino acids from human PHM-27. When each VIP precursor is divided functionally into 6 domains, the amino acid sequence homology between rat and human precursors ranges from 69 to 100%. In contrast, any domain exhibits an essentially equal degree of nucleotide sequence homology.

Rat VIP Rat PHI-27 VIP precursor VIP precursor mRNA Human PHM-27 Sequence homology

1. INTRODUCTION

Vasoactive intestinal polypeptide (VIP), a 28 amino acid peptide originally isolated from porcine duodenum [1], is present not only in gastrointestinal tissues but also neural tissues, possibly as a neurotransmitter [2,3]. VIP is structurally similar to members of the glucagon-secretin family, especially to porcine PHI-27 [4]. We found that the primary structure of the human VIP precursor, deduced from the DNA sequence complementary to the mRNA coding for human VIP, contains the sequences of both VIP and a novel PHI-27-like peptide, PHM-27 [5,6]. We reported that the transcription rate of the VIP precursor mRNA in human neuroblastoma cells is regulated by cyclic AMP [7].

Abbreviations: VIP, vasoactive intestinal polypeptide; PHI-27, peptide having amino-terminal histidine, carboxy-terminal isoleucine amide and 27 amino acid residues; PHM-27, peptide having amino-terminal histidine, carboxy-terminal methionine amide and 27 amino acid residues; bp, base pairs

* To whom correspondence should be addressed

Here, we have determined the DNA sequence complementary to the mRNA coding for rat VIP precursor. The comparative analysis of nucleotide and amino acid sequence homologies of rat and human VIP precursors implies that selection pressures during evolution have eliminated base substitutions which might result in amino acid replacements.

2. MATERIALS AND METHODS

2.1. Materials

Guanidinium thiocyanate was purchased from Fluka; oligo(dT)-cellulose from Pharmacia P-L Biochemicals; restriction endonucleases from Nippon Gene (Toyama, Japan) and Takara Shuzo (Kyoto); avian myelomatosis virus reverse transcriptase from Seikagaku Kogyo (Tokyo); calf thymus terminal deoxynucleotidyl transferase from Takara Shuzo; *E. coli* RNase H from Wako (Osaka); *E. coli* DNA ligase from Pharmacia P-L Biochemicals; *E. coli* DNA polymerase I from New England BioLabs; membrane filters for colony and blot hybridizations and DPT paper from Schleicher & Schuell; $[\alpha^{-32}P]dCTP$, dGTP, and TTP (spec. act. 3000 Ci/mmol) and an M13 clon-

Published by Elsevier Science Publishers B.V. (Biomedical Division) 00145793/85/\$3.30 © 1985 Federation of European Biochemical Societies **FEBS LETTERS**

A			1	Puta	tive	Sigr	nal i	Pept.	ıde		10					-					20		
	Rat 5	•••••	<u></u> -						-AG	Phe UUC	Le u CUG	Ala GCG	Ile AUC	Leu CUG	Thr ACA	Leu CUC	Phe UUC	Ser AGU	Val GUG	Leu CVG	Phe UUC	Ser UCA	63
	Human 5	*****	AUG C Met A	AC ACC	AGA Arg	AAU Asn	AAG Lys	GCC Ala	C Gln	C Leu	U	U Val	C Leu		U	U	C Leu			С			
Gln Ser Leu Al CAG UCG CUG GC A U UC Thr Ser	a Trp Pro L C UGG CCU C A	.eu Tyr WC UAU U C	1 30 Gly F GGG C A G Arg A	ro Pro CA CCU la	Ser UCU	Ser UCA GCU Ala	Val GUG C C Leu	Arg AGG	Leu UUG	Asp GAU G Gly	Asp GAC	40 Arg AGG A	Leu CUG A A Ile	Gln CAG CC Pro	Phe UUC U	Glu GAA G	G1y GGA	50 Ala GCA	Gly GGU AA Asn	Asp GAC A Glu	Pro CCU	50 Asp GAU -	150
Gln Val Ser Le CAA GUC UCU UU U A	u Lys Ala A A AAA GCA G A Glu	asp Ser AC UCU AU Ile	6 Asp I GAC A M	0 le Leu UC UUG G let	Gln CAG A	Asn AAU	Ala GCC A	Leu UUA	Ala GCG U	G1u GAG _A	Asn AAU	Asp GAC	70 Thr ACG A	Pro CCC	Tyr UAU	Tyr UAU	Asp GAU	Val GUG A	Ser UCC	Arg AGA	Asn AAU	Ala GCC	237
80 90 Rat PHI-27 100 Arg His Ala Asp Gly Val Phe Thr Ser Asp Tyr Ser Arg Ley Ley Gly Clo Yla Sor Ala Lyg Tyr Ley Cly Clo Yla Sor Ala																							
Arg His Ala As ACG CAU GCU GA	p GIY VAL P U GGA GUU U -	ne Inr WC ACC	Ser A AGC G U	sp Tyr AC UAC U Phe	AGU	Arg AGA A Lys	CUU CUU C	Leu CUG U	GIY GGU	GIn CAG A	AUU C Len	UCU	Ala GCC	Lys AA <u>A</u> —	Lys AAA G	Tyr UAC	Leu CUU	Glu GAG	Ser UCA U	Leu CUC U	Ile AUU G Met	Gly GGC A	324
110	250			1.110	120	190	На	ıman	PHM	-27	Leu			300)						nec		
Lys Arg Ile Se AAA CGA AUC AG U G U	r Ser Ser I C AGU AGC A A	le Ser UC UCG A	Glu A GAA G	sp Pro AC CCC U	Val GUG A	Pro CCG A	Val GUC	Lys AAA	Arg CGA U	Hís CAC	Ser UCU A	Asp GAU	Ala GCA	Val GUC	Phe UUC	Thr ACA U	Asp GAU C	Asn AAC	Tyr UAC UAC	Thr ACC	Arg CGC	Leu CUU	411
Vai	Asn		350							L									400				
140 Arg Lys Gln Me AGA AAG CAA AU A	t Ala Val L G GCU GUG A A	ys Lys AG AAA	Tyr L UAC U U	eu Asn UG AAC	Ser UCC A	<u>150</u> <u>Ile</u> AU <u>U</u> 	Leu CUA G	Asn AAU	Gly GGG A	Lys AAG	Arg AGG	Ser AGC	Ser AGU	Glu GAG	Gly GGA	160 Asp GAU A Glu	Ser UCU	Pro CCA C	Asp GAC	Phe UUC U	Leu CUU CA Pro	Glu GAA	498
17 Glu Leu Glu Ly GAG CUA GAG AA U A 500	0 s End End A UGA UGA					450	•																516
B 600 Rat GAAGGGUUCUUCUGG:GCAGAGGUUGAAGAAC::::::UC:::AGAGGAUUUCUUGAAGGAAAA::CA::AC::CAAG::UGAUUACAUUAUGAG::UUCUACAUUAUUGAAUUCAAGAA Human A A : A U A U CAACU CC U UG U G A U A A G AGG															GAA	610 620							
650 700 AACAACUUCCAUAGCAAAACCAAAUAAAA:::::UGUGUUGUGAUAUAUGUGGUUUC::CU:::UUAUGUAAUAACUGUGAUGUUUACAUUGUAAAUA:UAUUU:AGCA:CUCUAA A U CAUAU C A C AUU AGC A A G G ; GU 650 700														UAA	713 735								
AAUUCAUCUUUAGC U UG A 7	UCGUGAAAGGC _AAA 50	C GC	75 UUUCA <u>U</u>	0 AUGCUA G	UAUAI	ບບດຫ C	UU:: CU/	AACA	ممم، ا	алилі 800	JAUUI	U:AAU U	JGAU	AGGUZ A	AGAU : (CUAC ;	800 AUU G	AUUG :(GCAAU C	JUAUC A	CUGA:	A:G C	819 848
$\begin{array}{cccccccccccccccccccccccccccccccccccc$														CAG	933 961								
AUAGG:CCGCCGUG : AAU U	950 UUACAUAAA:: ACC	GCAAAAI	UAUCUA G	ACGGAA <u>A</u> U G 1000	:AACO U :	CAAA(U(CAU:A G AG	AUGG/ AUGG/	AAAI	UGGA(:: (10 GAUA C U	00 <u>C</u> UUG <i>I</i> C:	ACAA/	AAGG/ A	AUUUI	JCA:# G	AAU A 1050	GU:4 AU	AU::: GUC	:::UC GUU	C:UC A :	CA: : U	1034 1068
1050 GUGAUAGGGA::CUCCACCUCUCAUGGA:UUC:::::::AUCUCUCCGACUAGGAUUUGC:AAUCCCCAAAAGCUUCUUCGAGU::UGCUUCAG:CUAGGAAAAGCUCAACUUCCA U U C AC UU UU U A UG UUAAAAA AA:: U U : U A G : :::: CC A :: U :::UUC U : GG:AG 1100 1150														CCA AG	1136 1168								
1150 1200 ACCUGGA:::::GCUUC::::::GCUUC::::CCUUUCUGCUUUUGCCUGUGGAUGUGUAAGCUA:GAAGCCU::AACGGAGUGCU::UGAUU:UCCAGUAGUAAAUACUCUUU:CC ::::::::::::::::::::::::::::::::::::													1226 1275										
GUAAUCACUCACAA	1250 1300 3UAAUCACUCACAACACGUAUUUUGUCUUAUUGGCUUCCUUUGCUGAAAGUACAUUUGUAGACACAACUACUUUUUCCAAUGUGAUUGUAUGAAAUUAAAGACAGGAAUAAAGAU													GAU	1341								
A																							1270

56

ing kit from Amersham; an M13 sequencing kit from Takara Shuzo.

2.2. Probe DNA for colony and blot hybridizations

The 409-bp Sau3AI-EcoRI restriction fragment (nucleotide residues 148-556 in fig.1), which contains human VIP and PHM-27 cDNA sequences, was derived from human prepro-VIP/PHM-27 cDNA clone pVIP-1 [5,6]. This fragment was labelled by nick-translation [8] with $[\alpha^{-32}P]dCTP$ and used as a hybridization probe to screen for recombinant plasmids carrying rat VIP precursor cDNA sequences.

2.3. Purification of RNA containing rat VIP precursor mRNA and cDNA cloning

Total RNA was extracted from cerebral cortex of male Wistar rats as described previously [9]. About 400 μ g of poly(A)⁺ RNA isolated by oligo(dT)-cellulose chromatography was applied to a linear 5-25% sucrose gradient, centrifuged at 26000 rpm at 20°C for 20 h in a Beckman SW27.1 rotor, and fractionated [10]. Glyoxalated RNA from each fraction was electrophoresed on a 1.5% agarose gel and transferred to DPT paper [11]. The paper was hybridized with the nick-translated Sau3AI-EcoRI restriction fragment from human prepro-VIP/PHM-27 cDNA clone pVIP-1 and subjected to autoradiography [7]. RNA (about 9 μ g) was ethanol-precipitated from the hybridization-positive fraction. With this partially purified mRNA, cDNA cloning was performed according to the method of Okayama and Berg [12].

2.4. Transformation of E. coli strain DHl and screening

Transformation of *E. coli* strain DHl was carried out according to the method of Shigesada [13]. Ampicillin-resistant transformants were screened by colony hybridization [14] with the nick-translated *Sau3AI-EcoRI* restriction fragment from human prepro-VIP/PHM-27 cDNA clone pVIP-1. Sizes of cDNA inserts of candidate clones were estimated by Southern blot analysis [11].

2.5. DNA sequence analysis

The largest cDNA insert was cleaved with various restriction endonucleases and the cleaved fragments were subcloned in M13 vectors mp10 and mp11 [15]. The sequence of each restriction fragment was determined by the dideoxy chaintermination method [15].

3. RESULTS

The partially purified mRNA from rat cerebral cortex was 3-fold enriched over $poly(A)^+$ RNA for rat VIP precursor mRNA by fractionation after passage through the sucrose density gradient. The content of rat VIP precursor mRNA was estimated at 0.005% by northern blot hybridization assays using the human VIP precursor cDNA (pVIP-1), and the rat VIP precursor mRNA was found to be about 1600 nucleotides long (unpublished). With the partially purified mRNA, cDNA cloning was performed according to the method of Okayama and Berg [12]. In the first screening, 11 hybridization-positive clones were isolated from 800 000 approx. transformants by colony

Fig.1. Nucleotide and deduced amino acid sequences of rat VIP precursor mRNA cloned into pVIPrat-B, compared with human sequences. (A) The coding regions and (B) the 3'-nontranslated regions. Nucleotide residues are numbered in the 5' to 3' direction, beginning with the first residue of AUG triplet encoding the initiative methionine of the human VIP precursor mRNA. Amino acid residues are numbered beginning with the initiative methionine of the human VIP precursor [5,6]. The upper nucleotide sequence shows the rat VIP precursor mRNA and the deduced amino acid sequence is given above this. The nucleotide and amino acid differences found in the human sequence are displayed beneath the rat sequence. Nucleotide sequences are aligned to give maximum homology with the introduction of minimal deletions. Deletions are indicated by colons on a one-to-one basis. The hyphens indicate sequences that have not been determined. A possible site for cleavage of a signal peptide is after amino acid residue 21 and possible glycosylation sites are at amino acid residues 68-70 and 133-135 [5]. The polyadenylation signals (AAUAAA) present downstream of the translational termination site are underlined.

hybridization with the nick-translated Sau3AI-EcoRI restriction fragment from human prepro-VIP/PHM-27 cDNA clone pVIP-1. We rescreened these 11 clones twice, and 3 independent clones varrying rat VIP precursor cDNA sequences were isolated. One of the clones, pVIPrat-B, which carried the largest cDNA insert (about 1500 bp long), was subjected to nucleotide sequence analysis by using M13 cloning and sequencing methods [15].

The nucleotide sequence of the mRNA coding for rat VIP precursor protein is shown in fig.1. The amino acid sequence (residues 125-152) deduced from the nucleotide residues 373-456 coincides precisely to the amino acid sequence of human VIP [5]. The primary structure of rat VIP, deduced from the cDNA sequence of rat cerebral cortex in this study, is in agreement with that of rat VIP recently isolated from rat intestine [16].

The deduced amino acid sequence at residues 81-107 has histidine as amino-terminus and isoleucine as carboxy-terminus and consists of 27 amino acid residues. This amino acid sequence differs by 1, 2, and 4 amino acid(s) from bovine PHI-27, porcine PHI-27, and human PHM-27, respectively [4,5,17]. Although rat PHI-27-like peptide has not been isolated, we estimate that the sequence of nucleotide residues 241-321 corresponds to that of 'rat PHI-27'.

Thus, as shown in fig.1A, the rat VIP precursor contains both rat VIP and rat PHI-27, and has post-translational processing sites for generation of these two peptides. A pair of basic amino acid residues (Lys-Arg) precede the amino-terminus of rat VIP and only one basic amino acid (Arg) precedes the amino-terminus of rat PHI-27. A glycine and a pair of basic amino acids (Gly-Lys-Arg), a sequence which is known to be a carboxyterminal amidation signal [18], lie adjacent to the carboxy-terminus of both rat VIP and rat PHI-27. These suggest that both rat VIP and rat PHI-27 are liberated from their precursor by proteolytic processing, and that the peptides are carboxyterminally amidated.

Two translation termination codons, UGA (nucleotide residues 511-516), are present at a site 55 nucleotides downstream from the carboxy-terminus of rat VIP, as is observed in the nucleotide sequence of human VIP precursor mRNA [5,6], but the presumed initiation codon is

not found. As shown in fig.1A, our cDNA clone pVIPrat-B can encode 162 amino acids and human VIP precursor is 170 amino acids long. Thus, our cDNA clone pVIPrat-B may be missing 22 nucleotides of the translated sequence in addition to the 5'-nontranslated sequence.

As shown in fig.1B, the 3'-nontranslated regio of the rat VIP precursor mRNA is unusually long and has two polyadenylation sites, AAUAAA (nucleotide residues 633-638 and 1333-1338). The rat 3'-nontranslated region is 75% homologous to the human counterpart, when gaps are counted as one substitution regardless of their length.

4. DISCUSSION

In the preceding paper, we have shown the primary structure of human VIP precursor [5,6]. Here, nucleotide sequence analysis of the cloned cDNA pVIPrat-B has disclosed the primary structure of rat VIP precursor. Comparison of rat and human VIP precursors has revealed that the positioning of the processing sites for generation of VIP and PHI-27 in the rat VIP precursor is the same as that in the human precursor (fig.1A). As shown in fig.2, each VIP precursor protein is func-



Fig.2. Sequence homology of each functionally divided domain in rat and human VIP precursors and corresponding mRNAs. The structure of the VIP precursor is presented schematically in the upper part of the figure. Numbering of the amino acid and nucleotide residues is as in fig.1. Each VIP precursor is functionally divided into 6 domains by the post-translational processing sites, and percentage of homology is calculated in each domain. Amino acid sequence homology is shown by shaded boxes and nucleotide sequence homology is solid lines.

tionally divided into 6 domains by posttranslational processing sites (after amino acid residues 21, 80, 107, 124, and 152). The amino acid sequence for VIP is completely conserved in rat and human VIP precursors, while the degree of amino acid sequence homology of other domains varies from 69 to 90%. In contrast, at the nucleotide level, the degree of homology is 89% in the VIP domain and any domain exhibits an essentially equal degree of homology (79-89%). Although these findings suggest that rat and human VIP precursor genes have evolved from a common ancestral gene, the comparative analysis of nucleotide and amino acid sequence homologies of each domain in rat and human VIP precursors implies that selection pressures have eliminated base substitutions which might result in amino acid replacements. In other words, the degree of amino acid sequence conservation of the peptide during evolution might strongly contribute to its essential biological functions. In fact, VIP is conserved in various mammalian species [1,5,6,19,20] and exhibits important biological actions [21], but the physiological significance of PHI-27 and PHM-27 is still nuclear.

ACKNOWLEDGEMENTS

This work was supported in part by Grants-in-Aid for Scientific Research and for Cancer Research from the Ministry of Education, Science and Culture, Japan.

REFERENCES

- Mutt, V. and Said, S.I. (1974) Eur. J. Biochem. 42, 581-589.
- [2] Larsson, L.-I., Fahrenkrug, J., Schaffalitzky de Muckadell, O., Sundler, F., Håkanson, R. and Rehfeld J.F. (1976) Proc. Natl. Acad. Sci. USA 73, 3197-3200.

- [3] Bryant, M.G., Bloom, S.R., Polak, J.M., Albuquerque, R.H., Modlin, I. and Pearse, A.G.E. (1976) Lancet i, 991-993.
- [4] Tatemoto, K. and Mutt, V. (1981) Proc. Natl. Acad. Sci. USA 78, 6603-6607.
- [5] Itoh, N., Obata, K., Yanaihara, N. and Okamoto, H. (1983) Nature 304, 547-549.
- [6] Okamoto, H., Itoh, N. and Obata, K. (1983) Regul. Peptides 6, 320.
- [7] Hayakawa, Y., Obata, K., Itoh, N., Yanaihara, N. and Okamoto, H. (1984) J. Biol. Chem. 259, 9207-9211.
- [8] Weinstock, R., Sweet, R., Weiss, M., Cedar, H. and Axel, R. (1978) Proc. Natl. Acad. Sci. USA 75, 1299-1303.
- [9] Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. and Rutter, W.J. (1979) Biochemistry 18, 5294-5299.
- [10] Itoh, N., Nose, K. and Okamoto, H. (1979) Eur. J. Biochem. 97, 1-9.
- [11] Barinaga, M., Franco, R., Meinkoth, J., Ong, E. and Wahl, G.M. (1981) Methods for the Transfer of DNA, RNA and Protein to Nitrocellulose and Diazotized Paper Solid Supports, Schleicher & Schuell Inc., Keene, NH.
- [12] Okayama, H. and Berg, P. (1982) Mol. Cell. Biol. 2, 161-170.
- [13] Shigesada, K. (1983) Cell Technol. 2, 616–626 (in Japanese).
- [14] Hanahan, D. and Meselson, M. (1980) Gene 10, 63-67.
- [15] Messing, J. (1983) Methods Enzymol. 101, 20-78.
- [16] Dimaline, R., Reeve, J.R., Shively, J.E. and Hawke, D. (1984) Peptides 5, 183-187.
- [17] Tatemoto, K., Jörnvall, H., McDonald, T.J., Carlquist, M., Go, V.L.W., Johansson, C. and Mutt, V. (1984) FEBS Lett. 174, 258-261.
- [18] Bradbury, A.F., Finnie, M.D.A. and Smyth, D.G. (1982) Nature, 298, 686–688.
- [19] Carlquist, M., McDonald, T.J., Go, V.L.M., Bataille, D., Johansson, C. and Mutt, V. (1982) Horm. Metabol. Res. 14, 28-29.
- [20] Carlquist, M., Mutt, V. and Jörnvall, H. (1979) FEBS Lett. 108, 457-460.
- [21] Said, S.I. (ed) (1982) Vasoactive Intestinal Peptide, Raven Press, New York.